Bivalirudin: in patients with ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Bivalirudin is a direct thrombin inhibitor.
• ST-segment elevation myocardial infarction (STEMI) requires prompt reperfusion therapy.
• Percutaneous coronary intervention (PCI) is a primary treatment for STEMI.

Purpose of the Study:

• To compare the efficacy and safety of bivalirudin versus unfractionated heparin (UFH) plus a glycoprotein (GP) IIb/IIIa inhibitor in STEMI patients undergoing primary PCI.
• To evaluate short-term and long-term clinical outcomes, including net adverse clinical events (NACE) and major bleeding.

Main Methods:

• Randomized, open-label, multicentre HORIZONS-AMI trial.
• STEMI patients undergoing primary PCI.
• Comparison of bivalirudin versus UFH plus GP IIb/IIIa inhibitor.

Main Results:

• Bivalirudin significantly reduced 30-day NACE, primarily due to lower non-coronary-artery bypass grafting (CABG) major bleeding.
• No significant difference in 30-day major adverse cardiovascular events (MACE).
• Lower short- and long-term mortality rates with bivalirudin.
• Increased acute stent thrombosis within 24 hours, but no significant difference thereafter.

Conclusions:

• Bivalirudin is a safe and effective alternative to UFH plus GP IIb/IIIa inhibitors for STEMI patients undergoing primary PCI.
• Bivalirudin reduces bleeding complications without compromising cardiovascular outcomes.
• Long-term follow-up confirms sustained benefits and acceptable safety profile.